Advisors Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.28M Buy
28,481
+1,000
+4% +$82.4K 0.04% 557
2025
Q4
$2.34M Buy
27,481
+9,598
+54% +$788K 0.04% 551
2025
Q3
$1.39M Buy
17,883
+1,727
+11% +$135K 0.02% 701
2025
Q2
$1.26M Sell
16,156
-559
-3% -$41.7K 0.02% 702
2025
Q1
$1.21M Buy
16,715
+469
+3% +$33.6K 0.02% 700
2024
Q4
$1.2M Buy
16,246
+4,390
+37% +$307K 0.02% 699
2024
Q3
$782K Buy
11,856
+852
+8% +$61.9K 0.01% 796
2024
Q2
$1.02M Sell
11,004
-3,083
-22% -$273K 0.02% 720
2024
Q1
$1.35M Sell
14,087
-155
-1% -$13K 0.03% 664
2023
Q4
$1.09M Sell
14,242
-6,359
-31% -$442K 0.02% 705
2023
Q3
$1.43M Buy
20,601
+781
+4% +$62.8K 0.03% 601
2023
Q2
$1.87M Sell
19,820
-3,488
-15% -$303K 0.04% 532
2023
Q1
$1.93M Sell
23,308
-599
-3% -$47.1K 0.04% 534
2022
Q4
$1.78M Sell
23,907
-11,052
-32% -$852K 0.04% 538
2022
Q3
$2.89M Buy
34,959
+373
+1% +$35.9K 0.06% 371
2022
Q2
$3.29M Sell
34,586
-8,970
-21% -$929K 0.06% 342
2022
Q1
$5.13M Buy
43,556
+117
+0.3% +$13.1K 0.08% 267
2021
Q4
$5.63M Sell
43,439
-13,186
-23% -$1.54M 0.08% 256
2021
Q3
$6.41M Buy
+56,625
New +$6.46M 0.1% 204
2021
Q2
Sell
-55,845
Closed -$4.67M 1434
2021
Q1
$4.67M Sell
55,845
-4,740
-8% -$401K 0.07% 271
2020
Q4
$5.53M Sell
60,585
-6,641
-10% -$551K 0.09% 214
2020
Q3
$5.37M Buy
67,226
+1,076
+2% +$84K 0.1% 185
2020
Q2
$4.57M Sell
66,150
-10,521
-14% -$748K 0.09% 221
2020
Q1
$4.82M Sell
76,671
-8,109
-10% -$585K 0.11% 176
2019
Q4
$6.59M Sell
84,780
-1,002
-1% -$78.2K 0.12% 204
2019
Q3
$6.29M Sell
85,782
-2,796
-3% -$196K 0.12% 203
2019
Q2
$5.46M Sell
88,578
-15,057
-15% -$910K 0.1% 247
2019
Q1
$6.61M Buy
103,635
+12,204
+13% +$696K 0.12% 199
2018
Q4
$4.67M Buy
91,431
+3,930
+4% +$199K 0.09% 248
2018
Q3
$5.08M Buy
87,501
+3,861
+5% +$189K 0.08% 291
2018
Q2
$4.06M Buy
83,640
+17,175
+26% +$802K 0.07% 347
2018
Q1
$2.96M Sell
66,465
-20,217
-23% -$878K 0.05% 479
2017
Q4
$3.26M Sell
86,682
-14,508
-14% -$532K 0.05% 455
2017
Q3
$3.69M Sell
101,190
-20,487
-17% -$781K 0.06% 428
2017
Q2
$4.8M Sell
121,677
-21,669
-15% -$791K 0.08% 342
2017
Q1
$4.5M Sell
143,346
-101,643
-41% -$3.18M 0.08% 364
2016
Q4
$7.65M Sell
244,989
-22,104
-8% -$716K 0.13% 231
2016
Q3
$10.7M Sell
267,093
-33,075
-11% -$1.25M 0.18% 153
2016
Q2
$9.98M Sell
300,168
-25,818
-8% -$883K 0.16% 177
2016
Q1
$9.59M Buy
325,986
+41,988
+15% +$1.16M 0.16% 184
2015
Q4
$7.48M Buy
283,998
+81,192
+40% +$2.11M 0.12% 243
2015
Q3
$4.8M Buy
202,806
+43,914
+28% +$1.06M 0.08% 357
2015
Q2
$3.77M Buy
158,892
+28,860
+22% +$651K 0.05% 475
2015
Q1
$3.09M Buy
130,032
+37,962
+41% +$852K 0.04% 513
2014
Q4
$1.96M Buy
92,070
+43,074
+88% +$865K 0.03% 651
2014
Q3
$834K Buy
48,996
+3,582
+8% +$56.5K 0.01% 855
2014
Q2
$650K Sell
45,414
-6,240
-12% -$84.6K 0.01% 951
2014
Q1
$639K Sell
51,654
-6,258
-11% -$72.2K 0.01% 908
2013
Q4
$635K Sell
57,912
-7,734
-12% -$87.2K 0.01% 895
2013
Q3
$762K Buy
65,646
+1,782
+3% +$20.8K 0.01% 760
2013
Q2
$715K Buy
+63,864
New +$756K 0.01% 731

Other funds holding EW

Advisors Asset Management's EW Position: Q1 2026 in Review

Advisors Asset Management increased its Edwards Lifesciences (EW) stake by 3.6% in Q1 2026, buying an estimated $82.4K and bringing the position to 28,481 shares worth $2.28M. The position accounts for 0.04% of the portfolio, ranked #557.

Advisors Asset Management first reported a position in EW in Q2 2013 and has held it in 51 quarters since. The position peaked at $10.7M in Q3 2016. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Advisors Asset Management held 28,481 shares of Edwards Lifesciences worth $2.28M as of Q1 2026.
  • Advisors Asset Management bought 1,000 Edwards Lifesciences shares in Q1 2026, an estimated $82.4K.
  • Edwards Lifesciences made up 0.04% of Advisors Asset Management's portfolio in Q1 2026, its #557 holding.
  • Advisors Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
  • Advisors Asset Management's Edwards Lifesciences position peaked at $10.7M in Q3 2016.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.